Takeda Licenses Use of Kinaxo Proteomics Platform | GenomeWeb
NEW YORK (GenomeWeb News) – Kinaxo Biotechnologies will make its KinaTor chemical proteomics technology available to Takeda San Diego researchers in drug discovery, preclinical research, and clinical development under an agreement announced this week.
 
Terms of the deal were not disclosed.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.